全文获取类型
收费全文 | 5512篇 |
免费 | 584篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 183篇 |
妇产科学 | 113篇 |
基础医学 | 559篇 |
口腔科学 | 66篇 |
临床医学 | 690篇 |
内科学 | 815篇 |
皮肤病学 | 120篇 |
神经病学 | 544篇 |
特种医学 | 156篇 |
外科学 | 585篇 |
综合类 | 54篇 |
一般理论 | 7篇 |
预防医学 | 653篇 |
眼科学 | 40篇 |
药学 | 322篇 |
中国医学 | 3篇 |
肿瘤学 | 1131篇 |
出版年
2023年 | 37篇 |
2022年 | 67篇 |
2021年 | 152篇 |
2020年 | 98篇 |
2019年 | 139篇 |
2018年 | 204篇 |
2017年 | 162篇 |
2016年 | 163篇 |
2015年 | 192篇 |
2014年 | 271篇 |
2013年 | 342篇 |
2012年 | 498篇 |
2011年 | 531篇 |
2010年 | 257篇 |
2009年 | 240篇 |
2008年 | 324篇 |
2007年 | 326篇 |
2006年 | 326篇 |
2005年 | 272篇 |
2004年 | 282篇 |
2003年 | 218篇 |
2002年 | 190篇 |
2001年 | 54篇 |
2000年 | 78篇 |
1999年 | 56篇 |
1998年 | 47篇 |
1997年 | 38篇 |
1996年 | 25篇 |
1995年 | 28篇 |
1994年 | 18篇 |
1993年 | 25篇 |
1992年 | 40篇 |
1991年 | 36篇 |
1990年 | 33篇 |
1989年 | 35篇 |
1988年 | 31篇 |
1987年 | 25篇 |
1986年 | 25篇 |
1985年 | 19篇 |
1984年 | 21篇 |
1983年 | 17篇 |
1982年 | 10篇 |
1981年 | 12篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1977年 | 13篇 |
1976年 | 9篇 |
1975年 | 16篇 |
1974年 | 8篇 |
1973年 | 16篇 |
排序方式: 共有6104条查询结果,搜索用时 328 毫秒
1.
2.
3.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献4.
Growth Hormone Induces Recurrence of Infantile Hemangiomas After Apparent Involution: Evidence of Growth Hormone Receptors in Infantile Hemangioma
下载免费PDF全文
![点击此处可从《Pediatric dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Naikhoba C. O. Munabi B.A. Qian Kun Tan H.S. Maria C. Garzon M.D. Gerald G. Behr M.D. Carrie J. Shawber Ph.D. June K. Wu M.D. 《Pediatric dermatology》2015,32(4):539-543
Infantile hemangiomas (IHs) are the most common benign tumor of infancy, characterized by a natural history of early proliferation in the first months of life to eventual involution during childhood, often with residual fibrofatty tissue. Once involution has been achieved, IHs do not typically recur. We present two cases of exogenous growth hormone therapy resulting in the recurrence of IHs in late childhood, supported by radiological, immunohistochemical, in vitro, and in vivo evidence. 相似文献
5.
6.
7.
8.
9.
OBJECTIVE: This article 1) provides an overview of formal Health Sciences Teaching Scholars Programs as presented in medical education literature and 2) presents information about an innovative multidiscipline Teaching Scholars Program. METHOD: Health Sciences Teaching Scholars Programs and similar programs were reviewed in the medical education literature to identify similar and dissimilar characteristics. The WVU Teaching Scholars Program highlighted in this article is presented with a discussion of goals, objectives, target audiences, course length, session frequency, program topics, learning methods, and assessments of the programs. A summary of the WVU Teaching Scholars Program and two Teaching Scholars Programs at McGill University and the University of Toronto were presented at the Association for American Medical Colleges (AAMC) annual meeting in 2006 for input from the general medical education audience. RESULTS: Comparisons of Health Sciences Teaching Scholars Programs reveal that successful programs are uniquely shaped by their educational environments. Scholars report that they value learning new teaching methods and improving their educational careers. CONCLUSION: Teaching Scholars Programs are valuable for the development of enhancing both teaching and scholarship in Health Sciences Programs and must adapt to the uniqueness of their respective educational environments and must continue to nurture scholars beyond graduation. 相似文献
10.